Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy

Primary membranous nephropathy (pMN) is an autoimmune kidney disease and a common cause of nephrotic syndrome in adults. Rituximab is becoming a first line therapy for patients with persistent nephrotic syndrome with proven safety and efficacy, achieving remission in 60%–80% of cases. For the remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Teisseyre, Maxime, Cremoni, Marion, Boyer-Suavet, Sonia, Crepin, Thomas, Benzaken, Sylvia, Zorzi, Kévin, Esnault, Vincent, Brglez, Vesna, Seitz-Polski, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548826/
https://www.ncbi.nlm.nih.gov/pubmed/34721403
http://dx.doi.org/10.3389/fimmu.2021.738788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548826/
https://www.ncbi.nlm.nih.gov/pubmed/34721403
http://dx.doi.org/10.3389/fimmu.2021.738788

Ejemplares similares